Danish pharmaceutical company Novo Nordisk is reporting new results for its obesity drug Wegovy in children aged 6-11 with obesity.
In a phase 3 study, participants’ BMI fell by an average of 17.4 percent after 68 weeks, compared with 2.2 percent in the placebo group.
Almost 8 out of 10 children who received semaglutide saw their BMI fall by at least 10 percent, according to the study, and just over 40 percent of participants were no longer considered obese.
The study included 167 children, and the results have been published in the New England Journal of Medicine.








What do you think?